Palbociclib with PI3K/mTOR inhibitor PF-05212384 in patients with estrogen receptor positive (ER+) metastatic breast cancer reported promising preliminary anti-tumor activity with manageable toxicities [39]. This evidence concerns the gene PIK3CA and neoplasm.